Indicators
Indicators
Value
Direction
MACD(12,26,9)
-1.325
Neutral
RSI(14)
48.253
Neutral
STOCH(KDJ)(9,3,3)
28.674
Sell
ATR(14)
2.830
High Vlolatility
CCI(14)
-133.035
Sell
Williams %R
74.659
Sell
TRIX(12,20)
0.561
Sell
StochRSI(14)
9.116
Oversold
Harrow Inc
HROW46.677USD
-0.513-1.09%
Market hours （ET）Quotes delayed by 15 min
1.73BMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Harrow Inc
Currency: USD Updated: 2026-01-13Key Insights
Harrow Inc's fundamentals are relatively stable, with low ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 45 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 70.71.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Harrow Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Harrow Inc Highlights
StrengthsRisks
Harrow, Inc. is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the North American market. The Company offers a comprehensive portfolio of prescription and non-prescription pharmaceutical products. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in North America, all of which are marketed under the Harrow name. It owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. It owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, ILEVRO, FLAREX, NATACYN, ZERVIATE, BYQLOVI and others. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms. IHEEZO (chloroprocaine hydrochloride ophthalmic gel) 3% is a low-viscosity gel indicated for ocular surface anesthesia.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 125.31% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 199.61M.
Undervalued
The company’s latest PE is -361.78, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 21.63M shares, decreasing 9.11% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 1.86M shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.25.
Analyst Rating
Based on
8
analysts
Buy
Current Rating
70.714
Target Price
+51.16%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-01-13The current financial score of Harrow Inc is 8.71, ranking 42 out of 159 in the Pharmaceuticals industry. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 71.64M, representing a year-over-year increase of 45.44%, while its net profit experienced a year-over-year increase of 124.17%.
Score
Financials
5.90
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
10.00
Operational Efficiency
10.00
Growth Potential
10.00
Shareholder Returns
7.66
Harrow Inc's Company Valuation
Currency: USD Updated: 2026-01-13The current valuation score of Harrow Inc is 7.39, ranking 74 out of 159 in the Pharmaceuticals industry. Its current P/E ratio is -361.78, which is -96.97% below the recent high of -10.97 and -16.13% above the recent low of -420.12.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 45/159
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-01-13The current earnings forecast score of Harrow Inc is 8.75, ranking 10 out of 159 in the Pharmaceuticals industry. The average price target is 69.00, with a high of 94.00 and a low of 59.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
8
analysts
Buy
Current Rating
70.714
Target Price
+51.16%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
173
Total
6
Median
8
Average
Company name
Ratings
Analysts
Harrow Inc
HROW
8
Biogen Inc
BIIB
36
Amgen Inc
AMGN
35
Vertex Pharmaceuticals Inc
VRTX
33
Eli Lilly and Co
LLY
33
Gilead Sciences Inc
GILD
31
1
2
3
...
35
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-01-13The current price momentum score of Harrow Inc is 7.03, ranking 73 out of 159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 53.36 and the support level at 42.51, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
48.770
Sell
MA10
50.108
Sell
MA20
48.822
Sell
MA50
43.995
Buy
MA100
42.550
Buy
MA200
36.093
Buy
Institutional Confidence
Currency: USD Updated: 2026-01-13The current institutional shareholding score of Harrow Inc is 5.00, ranking 73 out of 159 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 58.41%, representing a quarter-over-quarter decrease of 0.61%. The largest institutional shareholder is The Vanguard, holding a total of 1.86M shares, representing 5.03% of shares outstanding, with 0.70% decrease in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
Opaleye Management Inc.
Baum (Mark L)
BlackRock Institutional Trust Company, N.A.
Kaufman (Daniel)
Boll (Andrew R)
State Street Investment Management (US)
Geode Capital Management, L.L.C.
1
2
Risk Assessment
Currency: USD Updated: 2026-01-13The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Harrow Inc is 5.08, ranking 77 out of 159 in the Pharmaceuticals industry. The company's beta value is 0.07. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. Harrow Inc’s latest ESG disclosure lags behind the Pharmaceuticals industry average, suggesting potential exposures in governance structure, environmental management, or social responsibility that may amplify risk and warrant ongoing monitoring.
Score
Beta vs S&P 500 index
0.07
VaR
+5.14%
240-Day Maximum Drawdown
+31.38%
240-Day Volatility
+75.05%
Return
Best Daily Return
60 days
+13.47%
120 days
+13.47%
5 years
+54.32%
Worst Daily Return
60 days
-8.35%
120 days
-8.35%
5 years
-36.01%
Sharpe Ratio
60 days
+1.45
120 days
+1.21
5 years
+0.92
Risk Assessment
Maximum Drawdown
240 days
+31.38%
3 years
+71.15%
5 years
+71.15%
Return-to-Drawdown Ratio
240 days
+1.46
3 years
+0.74
5 years
+1.70
Skewness
240 days
+0.72
3 years
+2.12
5 years
+1.97
Volatility
Realised Volatility
240 days
+75.05%
5 years
+71.65%
Standardised True Range
240 days
+4.45%
5 years
+2.47%
Downside Risk-Adjusted Return
120 days
+228.76%
240 days
+228.76%
Maximum Daily Upside Volatility
60 days
+49.97%
Maximum Daily Downside Volatility
60 days
+35.35%
Liquidity
Average Turnover Rate
60 days
+1.40%
120 days
+1.49%
5 years
--
Turnover Deviation
20 days
+25.47%
60 days
-2.61%
120 days
+3.57%
Peer Comparison
Pharmaceuticals
Harrow Inc
HROW
7.45 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Mckesson Corp
MCK
8.93 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Mirum Pharmaceuticals Inc
MIRM
8.78 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Prestige Consumer Healthcare Inc
PBH
8.66 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
ANI Pharmaceuticals Inc
ANIP
8.63 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Cardinal Health Inc
CAH
8.48 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
FAQs
How does TradingKey generate the Stock Score of Harrow Inc?
The TradingKey Stock Score provides a comprehensive assessment of Harrow Inc based on 34 indicators derived from over 100 underlying data points. These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Harrow Inc’s performance and outlook.
How do we generate the financial health score of Harrow Inc?
To generate the financial health score of Harrow Inc, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns. By integrating these comprehensive data, the financial health score not only reflects Harrow Inc's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Harrow Inc.
How do we generate the company valuation score of Harrow Inc?
To generate the company valuation score of Harrow Inc, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Harrow Inc’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value. By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Harrow Inc’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Harrow Inc.
How do we generate the earnings forecast score of Harrow Inc?
To calculate the earnings forecast score of Harrow Inc, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.Comparing these indicators against peers provides context for the stock’s performance and helps
anchor more realistic expectations.These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Harrow Inc’s future.
How do we generate the price momentum score of Harrow Inc?
When generating the price momentum score for Harrow Inc, we examine momentum indicators including support and resistance levels as well as volume metrics.Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.This comprehensive approach can reflect market sentiment and enable rational forecasts of Harrow Inc’s prices. A higher score indicates a more stable short-term price trend for Harrow Inc.
How do we generate the institutional confidence score of Harrow Inc?
To generate the institutional confidence score of Harrow Inc, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Harrow Inc’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Harrow Inc.
How do we generate the risk management score of Harrow Inc?
To assess the risk management score of Harrow Inc, we examine multiple key indicators related to returns, risk, volatility, and liquidity.The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.These indicators together provide a multi-dimensional understanding of Harrow Inc’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Harrow Inc.
